New Diagnostic Aids for Melanoma

Ferris, Laura K.; Harris, Ryan

doi:10.1016/j.det.2012.04.012

Cited by 46 publications

(35 citation statements)

References 62 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the upfront cost of the device is high, the supplies to image individual lesions cost only about $1 per lesion, allowing imaging of multiple lesions with minimal increased cost to the patient per lesion [80].…”

Section: Non-invasive Methods For Diagnosis Of Skin Disorders and Disementioning

confidence: 99%

Confocal Laser Scanning Microscopy as a Tool for the Investigation of Skin Drug Delivery Systems and Diagnosis of Skin Disorders

Rossetti¹,

Depieri²,

Bentley³

2013

Confocal Laser Microscopy - Principles and Applications in Medicine, Biology, and the Food Sciences

View full text Add to dashboard Cite

Section: Non-invasive Methods For Diagnosis Of Skin Disorders and Disementioning

confidence: 99%

Confocal Laser Scanning Microscopy as a Tool for the Investigation of Skin Drug Delivery Systems and Diagnosis of Skin Disorders

Rossetti¹,

Depieri²,

Bentley³

2013

Confocal Laser Microscopy - Principles and Applications in Medicine, Biology, and the Food Sciences

View full text Add to dashboard Cite

“…There are several commercially available devices for skin cancer detection and a magnitude of research in the field (18,19). As far as we know there are no commercial applications of a HIS.…”

Section: Discussionmentioning

confidence: 99%

Delineating Margins of Lentigo Maligna Using a Hyperspectral Imaging System

Neittaanmäki-Perttu¹,

Grönroos²,

Jeskanen³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

Lentigo maligna (LM) is an in situ form of melanoma which can progress into invasive lentigo maligna melanoma (LMM). Variations in the pigmentation and thus visibility of the tumour make assessment of lesion borders challenging. We tested hyperspectral imaging system (HIS) in in vivo preoperative delineation of LM and LMM margins. We compared lesion margins delineated by HIS with those estimated clinically, and confirmed histologically. A total of 14 LMs and 5 LMMs in 19 patients were included. HIS analysis matched the histo-pathological analysis in 18/19 (94.7%) cases while in 1/19 (5.3%) cases HIS showed lesion extension not confirmed by histopathology (false positives). Compared to clinical examination, HIS defined lesion borders more accurately in 10/19 (52.6%) of cases (wider, n = 7 or smaller, n = 3) while in 8/19 (42.1%) cases lesion borders were the same as delineated clinically as confirmed histologically. Thus, HIS is useful for the detection of subclinical LM/LMM borders.

show abstract

“…Those photophysical properties allowed researchers to conjugate QDs with variable cancer-specific molecules as folic acid or antibodies against specific cancer antigens (36-40). When QDs are conjugated with specific antimelanoma antibodies (e.g., HMB45, MART-1, and Tyrosinase), melanoma cells can be distinguished from normal melanocytes (41). However, the heavy metal composition of QDs, with its high toxicity and immunogenicity, hinders the wide application of QDs as an imaging modality for cancer (42,43).…”

Section: Nanomedicine For Melanoma Detection and Treatmentmentioning

confidence: 99%

Nanomedicine in Melanoma: Current Trends and Future Perspectives

El-Kenawy

Constantin

Hassan

et al. 2017

Cutaneous Melanoma: Etiology and Therapy

View full text Add to dashboard Cite

Abstract:As cutaneous melanoma is a highly aggressive and drug-resistant cancer, there is intense research focusing on developing new, efficient drugs. Nanomedicine focuses on developing different groups of nanomaterials for both diagnosis and therapy, and this combination of specific diagnosis and therapy is called theranostics. Nanomaterials tailored as delivery vehicles can be nanocapsules, nanorods, nanotubes, nanoshells, and nanocages. All these structures protect the intended drug against degradation and enhance its stability. The development and characterization of polymeric nanoparticles, polymeric micelles, liposomes, nanohydrogel, dendrimers, inorganic nanoparticles, and hybrid nanocarriers are among the delivery vehicles that transport different anticancer agents. Functionalization of nanocarriers with specific molecules, such as antibodies, can generate different smart nanodrugs for application in cancer therapy and/or diagnosis. Nanotherapeutic strategies deal with several shortcomings that comprise of tumor characteristics, biological barriers, biocompatibility, and so on. As nanostructures interact with various host biomolecules, comprehensive in vitro cellular models call for evaluation of physicochemical properties, dose, and time of action of nanomaterials, while in vivo assessments would provide valuable data regarding the level of absorption, tissue/organ distribution, and metabolism. The future perspectives in nanotechnology applied to cancer overcomes the translational barrier from the laboratory to the clinical application to potentially improve conventional theranostic techniques.

show abstract

New Diagnostic Aids for Melanoma

Cited by 46 publications

References 62 publications

Confocal Laser Scanning Microscopy as a Tool for the Investigation of Skin Drug Delivery Systems and Diagnosis of Skin Disorders

Confocal Laser Scanning Microscopy as a Tool for the Investigation of Skin Drug Delivery Systems and Diagnosis of Skin Disorders

Delineating Margins of Lentigo Maligna Using a Hyperspectral Imaging System

Nanomedicine in Melanoma: Current Trends and Future Perspectives

Contact Info

Product

Resources

About